Chromosome 11p15 has attracted considerable attention because of the biological importance of this region to human disease. Apart from being an important tumor suppressor locus showing loss of heterozygosity (LOH) in several adult and childhood cancers, 11p15 has been shown by linkage analysis to harbor the gene(s) for the Beckwith-Wiedemann syndrome. Furthermore, the clustering of known imprinted genes in the 11p15.5 region suggests that the target gene may also be imprinted. However, positional cloning efforts to identify the target genes have been complicated by the large size (∼10 Mb) and complexity of LOH at 11p15. Here, we have analyzed 94 matched normal and breast tumor samples using 17 polymorphic markers that map to 11p15.5-15.4. We have defined precisely the location of a breast tumor suppressor gene between the markers D11S1318 and D11S4088 (∼500 kb) within 11p15.5. LOH at this region occurred in ∼35-45% of breast tumors analyzed. In addition, we have fine-mapped a second, critical region of LOH, that spans the markers D11S1338-D11S1323 (∼336 kb) at 11p15.5-p15.4, that is lost in ∼55-60% of breast tumors. There is a striking correlation between the loss of the two 11p loci and the clinical and histopathological features of breast tumors. LOH at region 1 correlated significantly (P = 0.016) with early events in malignancy and invasiveness. In contrast, the loss of the more proximal region 2, is highly predictive (P = 0.012) of aggressive metastatic disease. Thus, two distinct tumor suppressor loci on chromosome 11p15 may contribute to tumor progression and metastasis in breast cancer. The fine mapping of this intriguing chromosomal region should facilitate the cloning of the target genes and provide critical clues to understanding the mechanisms that contribute to the evolution of adult and childhood cancers.
INTRODUCTION
Breast cancer is both genetically and clinically a heterogeneous and progressive disease. The severity of disease may be determined by the accumulation of alterations in multiple genes that regulate cell growth and proliferation. The inactivation of tumor suppressor genes, by a two-hit mechanism involving mutations and loss of heterozygosity (LOH), appears to be a common event in the genetic evolution of breast carcinomas (1) . Several chromosome arms, including 1p, 1q, 3p, 11p, 11q, 13q, 16q, 17p, 17q and 18q, have been reported to show moderate (20-40%) to high (>50%) frequencies of LOH in breast tumors (1) . This implies that multiple tumor suppressor genes are likely to be involved in the development and progression of breast cancer.
Genetic alterations at the short arm of chromosome 11 are a frequent event in the etiology of cancer (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Several childhood tumors demonstrate LOH for 11p, including rhabdomyosarcoma (7, 8) , adrenocortical carcinoma (9), hepatoblastoma (10), mesoblastic nephroma (11) and Wilms' tumors (WT) (12) . Recurrent LOH at 11p is also observed in adult tumors including bladder (13) , ovarian (14) , lung carcinomas (15) , testicular cancers (16) , hepatocellular carcinomas (17) and breast carcinomas (2) (3) (4) (5) (6) , suggesting the presence of one or more critical tumor suppressor gene(s) involved in several malignancies.
Birch et al. (18) have reported an increased risk of breast cancer among mothers of children with embryonal rhabdomyosarcoma, providing genetic evidence for the apparent high-risk association between these two tumor types. The familial association between breast cancer and rhabdomyosarcoma and the other childhood tumors may well be the consequence of alterations in chromosome 11p15. The ability of a tumor suppressor gene(s) on chromosome 11 to re-establish control of the malignant phenotype has been demonstrated by transfer of a normal human chromosome 11 to the breast cancer cell line MDA-MB-435 (19) . However, *To whom correspondence should be addressed. Tel: +1 216 445 6529; Fax: +1 216 445 6269; Email: karnikp@cesmtp.ccf.org positional cloning efforts to identify the target genes on 11p15 have been complicated by the large size of this region (∼10 Mb) and the complexity of LOH at 11p15.
With the goal of identifying the putative tumor suppressor gene(s) on chromosome 11p15, we have refined the minimal regions of LOH in this region, using a high-density marker analysis of 94 informative primary breast tumors and paired normal breast tissue. We have defined precisely and identified two distinct regions of chromosome 11p15.5-p15.4 that frequently are deleted in breast cancer. The association of LOH with clinical and histological parameters reveals the biological role of the putative tumor suppressor genes in the etiology of breast cancer.
RESULTS

Refinement of the tumor suppressor loci on chromosome 11p involved in breast cancer
Fluorescent PCR semi-automated genotyping (5) was used to detect and analyze allelic losses on chromosome 11 using a panel of 17 microsatellite markers. Previous studies have determined that this technique is more rapid and sensitive compared with the classical radioactive method in determining LOH in tumor DNAs (20) . To identify the smallest common deleted region on chromosome 11p15 in breast tumors, 94 paired normal-tumor DNAs were assessed for LOH at 17 chromosome 11p15-specific microsatellite markers. These markers encompass the chromosomal sub-regions 11p15.5-11p15.4, estimated to be ∼8-10 Mb (21,22) (Fig. 1) . The results indicate that the loss of all or part of chromosome 11p is a more common event in human breast cancer than previously appreciated (3, 4) . LOH occurred in at least one marker on the short arm of chromosome 11 in 56 of 94 (60%) informative tumors. The overall frequency of LOH for each marker varies from 16 to 60%, with two peaks seen at markers D11S1318 (45%) and D11S1338 (60%) (Fig. 1) . In addition to the 23% LOH at the D11S988 locus (Fig. 1 ), there was a high incidence of microsatellite instability (MSI) at this marker as we had described earlier (5) . Therefore, the possibility that MSI obscures the accurate determination of LOH at the D11S988 locus in some of these tumors cannot be ruled out.
Tumors 57, 94, 6 and 24 (Genescans; Fig. 2 ) are illustrative examples of LOH patterns seen on chromosome 11p15 and provide a critical description of the LOH regions. Interstitial deletions, examples of which are seen in tumors 57, 94, 6 and 24, were observed more commonly than loss of the entire chromosomal arm as seen in tumor 7 (Fig. 3) . In some cases, an example of which is seen at the marker D11S1997 in tumor 24 ( Fig. 2) , it was observed that the peak for the allele which loses heterozygosity does not change between normal and tumor tissues. Rather, the peak for the other allele increases by several fold in the tumor. Since the surrounding markers show LOH, we believe that this allelic imbalance represents LOH and not gene amplification.
The genotypes of the 13 representative breast tumors described in Figure 3 , along with other tumors analyzed (data not shown), serve to refine and identify two distinct regions of LOH on 11p15. Region 1 is encompassed by markers D11S1318 and D11S4088 and is defined by the LOH break points in tumors 57 and 94. Tumor 57 retained heterozygosity for the markers D11S2071, D11S1984, D11S1363, D11S922, TH and D11S1318, but showed LOH for the markers D11S4088, D11S1288, D11S860, D11S988 and D11S1758. This tumor also retained heterozygosity for all the remaining proximal markers. Tumor 94 showed LOH at markers D11S2071, D11S1984, D11S922, TH and D11S1318. This tumor was non-informative for the marker D11S1363 and retained heterozygosity at all the proximal markers. Tumors 94 and 57, therefore, refine the LOH region 1 to a distance of ∼500 kb between the markers D11S1318 and D11S4088. This distance was calculated based on the estimation of Reid et al. (23) and the sequence map of chromosome 11 (http://mcdermott.swmed.edu/). Importantly, these results narrow the region containing this tumor suppressor gene from 2 Mb reported earlier (3, 4) to ∼500 kb. Tumors 42, 57 and 94 are examples of tumors that contain interstitial deletions exclusively in region 1 (Fig. 3) .
The more centromeric region of LOH (region 2) is defined by breakpoints in the tumors 6 and 24 (Figures 2 and 3) . Tumors 6, 24, 35, 45 and 76 are examples of tumors that harbor interstitial deletions in region 2 (Fig. 3) . Tumor 6 showed LOH for the markers D11S988, D11S1758, D11S1760 and D11S1338, but retained heterozygosity at all the markers distal to D11S988 and at all the markers proximal to D11S1338. Tumor 24 was heterozygous for all the markers distal to D11S1323 but showed LOH at D11S1323, D11S1997, D11S866 and D11S1331. It is notable that tumors 6 and 24 exhibit LOH at either D11S1338 or D11S1323, while the other locus retains heterozygosity. This clearly indicates that region 2 is within the interval that spans the markers D11S1338-D11S1323, a distance of ∼336 kb based on the estimate of James et al. (22) and the sequence map of chromosome 11 (http://mcdermott.swmed.edu/). The yeast artificial chromosome (YAC) 847a12 that contains the markers D11S1338, D11S1323 and D11S1997 is ∼1.4 Mb in length and is non-chimeric (STS-based map of the human genome; http:// www-genome. wi.mit.edu). We have identified integrin-linked kinase (p59ILK) as a candidate gene for this locus. p59ILK previously was mapped to the CALC-HBBC region on chromosome 11p15 (24) . We have refined the map location of p59ILK and placed it on the YAC 847a12. PCR amplification of DNA from the YAC 847a12 with several different p59ILK primers produced the expected length fragments. No products were seen from a BAC DNA specific for the marker D11S1323 or from yeast DNA (data not shown).
A total of five tumors, examples of which were seen in tumors 7, 20, 26, 30 and 34 ( Fig. 3 ), appeared to have lost both of the regions on the chromosome 11p arm. In tumor 7 ( Fig. 3) , 14 of the 17 markers analyzed showed LOH. This tumor was non-informative for the markers D11S2071, D11S1363 and D11S1758. The probability of three or more allelic losses in the same fragment being caused by independent events is small, and a series of LOH in contiguous markers is more likely to be due to deletion of the entire segment. In most instances, however, LOH on 11p15 appeared to be interstitial (e.g. tumors 20, 26, 30 and 34) and, therefore, restricted to relatively small chromosomal regions.
These data attest the presence of two distinct regions of LOH within 11p15.5-15.4. Region 1 lies between markers D11S1318 and D11S4088 (∼500 kb) and region 2 lies between markers D11S1338 and D11S1323 (∼336 kb). As described in Figure 3 , the two regions were lost in different tumors, although in some tumors both of these regions appeared to be lost due either to interstitial deletions or to the loss of the entire 11p arm.
Negrini et al. (4) previously have reported a third LOH region, towards the telomere, between the markers D11S576 and D11S1318. The percentage LOH that we observe for the telomeric markers D11S2071, D11S1984, D11S1363 and D11S922 (16-22%) is consistent with the observations of Negrini et al. (4) . However, the percentage LOH for these markers is well within the background LOH seen at the remaining 11p markers (Fig. 1 ). In addition, we did not identify tumors that showed LOH exclusively in the telomeric markers D11S2071-D11S922. In our tumor panel, LOH at the distal markers occurred in concert with LOH at region 1. We therefore did not represent the distal region as an independent and third region of LOH.
Correlation between loss of heterozygosity at 11p and pathological features of breast tumors
Conflicting clinical data and clinical correlations of 11p LOH in breast cancer exist in the literature. This study was initiated with those concerns in mind. To examine the role of 11p LOH in breast cancer and to determine if the two regions are involved differentially in predicting the clinical course of this disease, we correlated our LOH data with the various clinical and histological parameters (Table 1) . All tumors described in Table 1 were infiltrating ductal carcinomas, which account for the largest single category of mammary carcinomas. The histological classification of the tumors, described under clinical features, was based on the WHO classification (25) . Tumors were subdivided into two categories: (i) tumors that had lost only region 1 and (ii) tumors that had lost only region 2. Clinical features of breast tumors are summarized as frequencies and percentages, separately for each region. The χ 2 test was used to compare these features between regions 1 and 2. All statistical tests were performed using a 5% level of significance.
A correlation was observed between LOH in region 1 and breast tumors containing ductal carcinoma in situ (DCIS) synchronous with invasive carcinoma. Fifteen percent (4/26) of ductal tumors with LOH in region 1 contained breast cancer tissues with synchronous DCIS and invasive carcinoma, while none of the tumors with LOH in region 2 contained a DCIS component (P = 0.016). DCIS of the breast is considered a pre-invasive stage of breast cancer and may be a precursor of infiltrating breast cancer (26) . Although the number of tumors analyzed is small, the statistically significant association between LOH in region 1 and such tumors suggests the involvement of a target gene in this region with early events in malignancy or invasiveness. The statistical analysis showed a significant association between 11p LOH and tumor ploidy. The majority of tumors (16/24) with region 1 LOH were either diploid or near diploid (P < 0.001). In contrast, the majority of tumors with region 2 LOH, were aneuploid (P < 0.001).
A trend was also observed between LOH at 11p and S-phase fraction (SPF). Fifty four percent of tumors with LOH in region 2, had a high SPF (>10% of cells in S-phase), compared with only 32% tumors with LOH in region 1. However, due to the small number of tumors in each category, statistical significance could not be established. It has been suggested that abnormal ploidy or elevated SPF identifies patients with shorter survival, and worsened disease-free survival, as well as being associated with poor outcome in locoregional control of the disease (27) . The association between LOH at region 2 and tumors with high SPF and abnormal ploidy, that we observe, is therefore very relevant.
A striking correlation was observed between loss of region 2 and lymphatic invasion. Importantly, 69% of patients with 11p LOH in region 2 showed lymphatic invasion, whereas this infiltration was present in only 29% of patients with region 1 LOH. Thus, tumors that had lost region 2 reveal a significantly higher incidence of metastasis to a regional lymph node(s) (P = 0.012) than tumors that had lost region 1. Tumors that had lost the entire 11p arm, or had lost both regions, showed the clinicopathological features of tumors that had lost region 2. We also observed the trend that LOH in region 2 occurs more frequently in higher grade (grade III) tumors than LOH in region 1. Thus, LOH at region 2 may be a late event in mammary tumorigenesis, potentially enabling a clone of previously transformed cells to exhibit greater biological aggressiveness.
DISCUSSION
We have identified two distinct regions on chromosome 11p15 that are subject to LOH during breast tumor progression and metastasis. The high frequency of somatic loss of genetic information and the striking clinical correlation observed suggest their role in the pathogenesis of breast cancer.
We have defined precisely and narrowed the location of the putative tumor suppressor gene in region 1 from ∼2 Mb (3,4) to ∼500 kb. The critical region appears to extend between the markers D11S1318 and D11S4088 at 11p15.5. Previous studies (3,4) had only been able to place the putative gene in the larger overlapping area between TH and D11S988 (Fig. 4) . Although LOH frequencies for this region are consistent (24-45%, this report; 35%, ref. 3 and 22%, ref. 4) , the peak incidence of LOH in this report is highest at D11S1318, ∼1 Mb distal to the peak at D11S860 reported by Winquist et al. (3) and Negrini et al. (4) . This discrepancy may reflect the characteristics of the tumor samples analyzed or a difference in interpretation of the corresponding allelic patterns. LOH involving region 1 coincides with regions implicated in the pathogenesis of rhabdomyosarcoma (7, 8) , WT (7), ovarian carcinoma (14) , stomach adenocarcinoma (28) and with a region conferring tumor suppressor activity (7), non-small cell lung carcinoma (43) , rhabdomyosarcoma (7), Beckwith-Wiedemann syndrome (31) and in stomach adenocarcinoma (28) .
previously identified by genetic complementation experiments (29) . Reid et al. (30) have used a functional assay to localize a 11p15.5 tumor suppressor gene that maps to this region in the G401 cell line. It is interesting to note that the physical map and contig of the BWSCR1-WT2 region described recently (23) overlaps with our LOH region 1. Inversions and translocations at chromosome band 11p15.5, associated with malignant rhabdoid tumors and Beckwith-Wiedemann syndrome (31), also overlap with both regions of LOH in this study. It remains to be determined whether a single pleiotropic gene or a cluster of tumor suppressor genes play a role in the genesis of different cancers, possibly at different stages of tumor development and progression.
In childhood tumors such as WT and embryonal rhabdomyosarcoma, there is a strong bias toward loss of maternal 11p15 markers (32) , suggesting the existence of an imprinted tumor suppressor gene in region 1. Since LOH for 11p15 is a common event in several adult tumors, a similar bias in allele loss could also be expected in the latter. Although the existence of parental bias towards LOH of 11p15 markers has not yet been demonstrated in adult tumors, two genes that map to 11p15, namely human insulin-like growth factor II gene (IGF2) and H19, are known to be expressed monoallelically in adult tissues (33, 34) , suggesting that genomic imprinting may be maintained in adult tissues. As illustrated in Figure 4 , several genes that map to the LOH region 1 are subject to imprinting. It has been suggested that deregulation of imprinting may play a role during tumorigenesis (35, 36) . One model proposes that inappropriate methylation (hypermethylation) silences one copy of a tumor suppressor gene (36) . This could be due to inappropriate activation of, or mutations in imprintor genes (37) . If the first 'hit' represents the non-expression of one of the alleles due to the imprinting process, the second 'hit' may be mutational or may result from loss of all or part of the chromosome carrying the remaining functional tumor suppressor allele, thereby fulfilling Knudson's 'two-hit' hypothesis (38) . Hypermethylation as an alternative pathway for tumor suppressor gene inactivation has been demonstrated elegantly for the retinoblastoma (Rb1) (39), the von Hippel Landau (VHL) syndrome (40) , and the p16 tumor suppressor genes (37) .
The other mechanism of altered imprinting that may affect tumorigenesis involves a gene activation hypothesis (36) that results in the reactivation of the silent allele due to the relaxation or loss of imprinting (LOI). LOI mutations have been detected at H19, IGF2, and to a lesser extent at p57KIP2 in WT and BWS (35) . LOI of IGF2 has been observed in benign and malignant breast tumors, in other adult and childhood tumors, and in a subgroup of patients with BWS (35, 41) . IGF2 is a potent mitogen with autocrine and paracrine effects, and the biallelic expression and possible increased dosage of the growth factor may explain the somatic overgrowth characteristics found in BWS patients and may play a role in tumor development. Although IGF2 maps outside the LOH region 1, the presence of novel genes that map to region 1 that may have similar mitogenic effects cannot be ruled out. p57KIP2 (42) The second hot-spot of LOH (region 2) in breast tumors is defined by markers D11S1338-D11S1323, and spans a distance of ∼336 kb (22) . Region 2 is centromeric to the putative WT2 gene (region 1) and overlaps with LOH regions previously described for breast cancer (2) and non-small cell lung carcinoma (43) . Importantly, we have refined this region from 5-10 Mb described earlier (2, 43) to ∼336 kb, with the highest incidence of LOH at the marker D11S1338. Previous studies (2, 43) , have only analyzed a few markers, sparsely distributed in the region proximal to HBB. Our study, therefore, is the first report of a detailed analysis of markers proximal to HBB that has considerably refined the boundaries of LOH in region 2.
We observed a significant correlation between LOH at the two chromosomal regions and the clinical and pathological parameters of the breast tumors. LOH in region 1 correlated with tumors that contain ductal carcinoma in situ synchronous with invasive carcinoma. This suggests that the loss of a critical gene in this region may be responsible for early events in malignancy or invasiveness. LOH at region 2 correlated with clinical parameters which portend a more aggressive tumor and a more ominous outlook for the patient, such as aneuploidy, high S-phase fraction and the presence of metastasis in regional lymph nodes. The association between 11p LOH, tumor progression and metastasis that we describe is analogous to the observations made in other epithelial tumors including breast cancer (3, 6) . For example, LOH at 11p correlated with advanced T stage and nodal involvement in non-small cell lung carcinoma (44) as well as subclonal progression, hepatic involvement (45) and poor survival in ovarian and breast carcinomas (3, 46) . Phillips et al. (19) have shown that micro-cell-mediated transfer of a normal human chromosome 11 into the highly metastatic breast cancer cell line MDA-MB-435 had no effect on tumorigenecity in nude mice, but suppressed metastasis to the lung and regional lymph nodes. This further supports the observation that chromosome 11 harbors a metastasis suppressor gene. The integrin-linked kinase gene (24) has been shown to induce anchorage-independent growth and a tumorigenic phenotype in rodents. We have refined the map location of p59ILK, and placed this gene on the YAC 847a12 that spans the markers D11S1338 and D11S1323. Thus, p59ILK is a tumor suppressor candidate for region 2.
It is not clear if LOH involving regions 1 and 2 act independently or synergistically in breast tumors. The identification of two subsets of tumors that have lost either region 1 or region 2 suggests that LOH at the two regions occurs independently and perhaps at different time points during breast tumor progression. This is consistent with the possibility that at least two tumor suppressor genes involved in the progression of breast cancer are located on the chromosome 11p15.5-15.4. These genes may function at distinct stages in the development and progression of breast cancer; alternatively, different target genes may be inactivated in different tumors. It is possible that specific subsets of tumors are defined by the particular set of mutations that they contain, which results in the clinical heterogeneity that is frequently seen in breast cancer.
Chromosome 11p15 contains several imprinted genes and two or more tumor suppressor genes. The fine mapping of this intriguing chromosomal region should facilitate the identification of novel genes, the evaluation of candidate genes and the establishment of the mechanisms whereby they contribute to the evolution of adult and childhood cancers.
MATERIALS AND METHODS
Patient materials and preparation of genomic DNA
Primary tumor and adjacent normal breast tissue samples were obtained from 94 randomly selected breast cancer patients undergoing mastectomy at the Cleveland Clinic Foundation (CCF). Samples of these tumors and corresponding non-involved tissue from each patient were collected at the time of surgery, snap-frozen and transferred to -80_C. Clinical and histopathological features of the tumors described in Table 1 were performed by the Pathology Department at CCF and were revealed only after the LOH study had been completed. The breast tumors described in Table 1 were classified according to the WHO classification (25) . Tumor grading described in Table 1 was based on the ScarffBloom-Richardson method (25) . DNA ploidy and S-phase determinations were done using the fine needle aspiration method (5) . ER and PR status were done using the Ventana 320 automated immunostandard and the modified labeled streptavidin biotin technique (5) .
An initial cryostat section was stained with H&E stain to determine the proportion of contaminating normal tissue, and only DNA purified from specimens thought to be highly enriched in tumor tissue was used for PCR. Generally we use tumor samples that contain <40% contamination of normal cells. In cases where LOH is questionable, where possible, regions containing a high proportion of normal tissue were physically removed from the original block by microdissection followed by DNA isolation. These improvements combined with the automatic quantitation of results using the Genescan Analysis have given us a better indication of LOH in tumor samples. Genomic DNA was isolated from normal and tumor tissue samples as described earlier (5) and quantitated by determining the optical densities at 260 and 280 nm.
Microsatellite polymorphisms and primers
DNA sequences flanking polymorphic microsatellite loci on chromosome 11p15.5 were obtained from the chromosome 11 databases and the Genome Data Base (GDB). Dye-labeled (FAM or HEX; Applied Biosystems) primers were either obtained from Research Genetics (Huntsville, AL) or synthesized as described earlier (5) . Only one primer in each pair was fluorescently labeled so that only one DNA strand was detected on the gel. The physical distances between the polymorphic loci were calculated based on the sequence map of chromosome 11 (http://mcdermott.swmed.edu/) and the radiation hybrid map of James et al. (22) . According to their calculation, 1 CR 9000 = 50.2 kb.
Polymerase chain reaction (PCR) and analysis of PCR products using Genescan software PCR of the DNA sequences was performed as described (5) . PCR products were analyzed on Seaquate 6% DNA sequencing gels (Garvin, OK) in 1× TBE buffer in a Model 373A automated fluorescent DNA sequencer (Applied Biosystems) which is a four-color detection system. One µl of each PCR reaction was combined with 4 µl of formamide and 0.5 µl of a fluorescent size marker (ROX 350; Applied Biosystems). The gel was run for 6 h at 30 W. During electrophoresis, the fluorescence detected in the laser scanning region was collected and stored using the Genescan Collection software (Applied Biosystems). The fluorescent gel data collected during the run were analyzed automatically by the Genescan Analysis program (Applied Biosystems) at the end of each run. Each fluorescent peak was quantitated in terms of size (in base pairs), peak height and peak area.
LOH analysis with Genescan
Fluorescent technology (5) was used to detect and analyze CA repeat sequences. The ratio of alleles was calculated for each normal and tumor sample and then the tumor ratio was divided by the normal ratio, i.e. T1:T2/N1:N2, where T1 and N1 are the area values of the shorter length allele and T2 and N2 are area values of the longer allele product peak for tumor and normal respectively. We assigned a ratio of 0.70 or less to be indicative of LOH on the basis that tumors containing no normal contaminating cells and showing complete allele loss would theoretically give a ratio of 0.0, but because some tumors in this series contained an estimated 30-40% normal stromal cells (interspersed among the tumor cells), complete allele loss in these tumors would give an allele ratio of only 0.70. At least three independent sets of results were used to confirm LOH in each tumor.
Statistical analysis
Clinical features of breast tumors are summarized as frequencies and percentages, separately for each LOH region. The χ 2 test was used to compare these features between regions 1 and 2. All statistical tests were performed using a 5% level of significance.
